Oxaliplatin, 5-fluorouracil and Leucovorin (FOLFOX-4) Combination Chemotherapy as a Salvage Treatment in Advanced Gastric Cancer
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose :This study was designed to determine the efficacy and safety of FOLFOX-4 chemotherapy as a salvage treatment for patients with advanced gastric cancer (AGC). Materials and Methods :The AGC patients with an ECOG performance status of 0∼1 and progressive disease after prior treatments were registered onto this phase II trial. The patients received oxaliplatin (85 mg/m2 on day 1), leucovorin (200 mg/m2 on days 1 and 2) and 5-fluorouracil (400 mg/m2 as a bolus and 600 mg/m2 as a 22-hour infusion on days 1 and 2) every 2 weeks. Results :For the 42 treated patients, a total of 228 chemotherapy cycles (median: 5, range: 1∼12) were administered. Twenty-nine patients (69%) received FOLFOX-4 chemotherapy as a third-(50%) or fourth-line (19%) treatment. On the intent-to-treat analysis, 9 patients (21%) achieved a partial response, which was maintained for 4.6 months. The median progressionfree survival and overall survival were 3.0 months and 6.2 months, respectively. The frequently encountered toxicities were neutropenia and gastrointestinal side effects, including anorexia. Although there was one possible treatment-related death, the toxicity profiles were generally predictable and manageable. Conclusion :Salvage chemotherapy with FOLFOX-4 is an effective and tolerable regimen for those heavily pretreated AGC patients who have a good performance status.
Abstract
Purpose :This study was designed to determine the efficacy and safety of FOLFOX-4 chemotherapy as a salvage treatment for patients with advanced gastric cancer (AGC). Materials and Methods :The AGC patients with an ECOG performance status of 0∼1 and progressive disease after prior treatments were registered onto this phase II trial. The patients received oxaliplatin (85 mg/m2 on day 1), leucovorin (200 mg/m2 on days 1 and 2) and 5-fluorouracil (400 mg/m2 as a bolus and 600 mg/m2 as a 22-hour infusion on days 1 and 2) every 2 weeks. Results :For the 42 treated patients, a total of 228 chemotherapy cycles (median: 5, range: 1∼12) were administered. Twenty-nine patients (69%) received FOLFOX-4 chemotherapy as a third-(50%) or fourth-line (19%) treatment. On the intent-to-treat analysis, 9 patients (21%) achieved a partial response, which was maintained for 4.6 months. The median progressionfree survival and overall survival were 3.0 months and 6.2 months, respectively. The frequently encountered toxicities were neutropenia and gastrointestinal side effects, including anorexia. Although there was one possible treatment-related death, the toxicity profiles were generally predictable and manageable. Conclusion :Salvage chemotherapy with FOLFOX-4 is an effective and tolerable regimen for those heavily pretreated AGC patients who have a good performance status.
참고문헌 (24)
- Annual report on the cause of death statistics (based on vital registration), "Korea National Statistical Office", ~ (2007)
- "Annual report of Korea central cancer registry (published in 2008)//Ministry Health and Welfare/"[URL]
- Glimelius B, "Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer", Ann Oncol, 8, pp.163~168 (1997)
- Murad AM, "Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer", Cancer, 72, pp.37~41 (1993)
- Pyrhonen S, "Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive carealone in patients with non-resectable gastric cancer", Br J Cancer, 71, pp.587~591 (1995)
- Rixe O, "Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel", Biochem Pharmacol, 52, pp.1855~1865 (1996)
- Becouarn Y, "Oxaliplatin: available data in noncolorectal gastrointestinal malignancies", Crit Rev Oncol Hematol, 40, pp.265~272 (2001)
- Bleiberg H, "Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer", Semin Oncol, 25, pp.32~39 (1998)
- de Gramont A, "Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer", J Clin Oncol, 18, pp.2938~1947 (2000)
- Cavanna L, "Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC)", Am J Clin Oncol, 29, pp.371~375 (2006)
- De Vita F, "A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients", Br J Cancer, 92, pp.1644~1649 (2005)
- Assersohn L, "Phase II study of irinotecan and 5-fluorouracil", leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma, 2004, pp.15, 64~69
- Cascinu S, "Phase II study of paclitaxel in pretreated advanced gastric cancer", Anticancer Drugs, 9, pp.307~310 (1998)
- Park SH, "Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy", CancerChemother Pharmacol, 57, pp.289~294 (2006)
- Sencan O, "The symptomatic benefit (the clinical benefit response) from the second-linechemotherapy in patients with advanced gastric adenocarcinoma", Eur J Cancer Care, 17, pp.26~32 (2008)
- Stathopoulos GP, "Paclitaxel and carboplatin in pretreated advanced gastric cancer: a phase II study", Oncol Rep, 9, pp.89~92 (2002)
- Thuss-Patience PC, "Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)", J Clin Oncol, 27, pp.4540~ (2009), abstr
- Kim DY, "Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advancedgastric cancer", Ann Oncol, 14, pp.383~387 (2003)
- Seo HY, "Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis", Cancer Chemother Pharmacol, 63, pp.433~439 (2009)
- Chun JH, "Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy", Jpn J Clin Oncol, 34, pp.8~13 (2004)
- Jo JC, "Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis", Jpn J Clin Oncol, 37, pp.936~941 (2007)
- Cersosimo RJ, "Oxaliplatin-associated neuropathy: a review", Ann Pharmacother, 39, pp.128~135 (2005)
- Park SH, "Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study", Anticancer Drugs, 19, pp.303~307 (2008)
- Wilson D, "Review of second-line chemotherapy for advanced gastric adenocarcinoma", Clin Oncol, 17, pp.81~90 (2005)